Noxopharm Ltd has released a press release.
Promising Interim Clinical Data for NOX66
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- 1st Patient treated in Lupin Study at St Vincents Hospital
- UNSW collaboration confirms drug designed for stroke victims
- Australian NOX66 - Radiotherapy Study Opens
- Establishment of Nyrada Inc.
- Positive Clinical Outcomes for NOX66 at ESMO Conference
Later from Noxopharm
- Clarification of Incorrect Information
- NYX-104 delivers Key Proof-of-Concept in Stroke Animal Model
- Nyrada Inc Opens Capital Raise - Memorandum Released
- EOY Guidance on 2018 NOX66 Clinical Development Strategy
- NOX receives FY17 R&D Tax Rebate
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm